<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354418</url>
  </required_header>
  <id_info>
    <org_study_id>18124</org_study_id>
    <secondary_id>CL2010-18</secondary_id>
    <secondary_id>P08340</secondary_id>
    <nct_id>NCT01354418</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)</brief_title>
  <official_title>A Randomized Crossover Bioequivalence Study Comparing a Single Dose of Phenylephrine HCl 30 mg Extended Release Tablet to Three Phenylephrine HCl 10 mg Immediate Release Tablets Each Consecutively Dosed Four Hours Apart Under Fed and Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the food-effect bioavailability of an extended release formulation of
      phenylephrine HCl and its bioequivalence to the marketed immediate release phenylephrine HCl
      product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of phenylephrine</measure>
    <time_frame>0 hours to time of maximum observed plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of phenylephrine</measure>
    <time_frame>0 hours to time of maximum observed plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC[0-t])</measure>
    <time_frame>0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from time 0 to infinity (AUC[0-∞])</measure>
    <time_frame>0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal rate constant (λz)</measure>
    <time_frame>0 hours to time of last measurable plasma concentration of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>0 hours to t1/2 of phenylephrine (blood samples will be collected up to 24 hours after first administration of study treatment)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Nasal Congestion</condition>
  <arm_group>
    <arm_group_label>Phenylephrine HCl Extended Release - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine HCl Extended Release - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine HCl Immediate Release - Fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine HCl Immediate Release - Fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine HCl Extended Release</intervention_name>
    <description>One phenylephrine HCl 30 mg extended release tablet orally</description>
    <arm_group_label>Phenylephrine HCl Extended Release - Fasted</arm_group_label>
    <arm_group_label>Phenylephrine HCl Extended Release - Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine HCl Immediate Release</intervention_name>
    <description>One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses</description>
    <arm_group_label>Phenylephrine HCl Immediate Release - Fasted</arm_group_label>
    <arm_group_label>Phenylephrine HCl Immediate Release - Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Female participants must not be pregnant

          -  Agrees to use two acceptable methods of birth control throughout the study

          -  Agrees not to take monoamine oxidase inhibitor (MAOI) for 2 weeks prior to, during,
             and 2 weeks after the end of the study

        Exclusion Criteria:

          -  Any significant medical condition which is a contraindication to the use of
             phenylephrine HCl, might interfere with the study, or requires treatment expected to
             affect blood pressure

          -  Any infectious disease within 4 weeks prior to initial treatment administration

          -  History of malignancy, except basal cell carcinoma

          -  Cannot comply with requirement to abstain from the use of any drugs (except
             acetaminophen or herbal/vitamin supplements) within 14 days prior to study and alcohol
             or xanthine-containing substances (coffee, chocolate) within 72 hours prior to study

          -  Received an investigational drug within thirty days prior to study drug dosing

          -  Known or apparent current or former drug addicts or alcoholics

          -  Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen,
             or hepatitis C antibody

          -  Cannot accept a high-fat, high-calorie breakfast

          -  Known allergy or intolerance to phenylephrine HCl

          -  Have used phenylephrine-containing product within 2 weeks prior to study start

          -  Have smoked tobacco, used tobacco products, or used a nicotine-containing smoking
             cessation aid within the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

